LY 288513

Known as: LY288513 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Cholecystokinin antagonists (part 1): Antinociceptive, anxiolytic and antidepressant effects of N-(5-methyl-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylureas and carboxamides.
The SAR optimization of the pyrazoline template resulted in novel 3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-indole… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • table 1
Is this relevant?
2004
2004
Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague–Dawley rats using elevated plus-maze test apparatus
This study investigated the behavioral mechanisms underlying the anxiogenic, or anxiolytic mediated effects of CCK(2) receptor… (More)
Is this relevant?
1998
1998
Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat
Defensive rage behavior is mediated over a descending pathway from the medial hypothalamus to the dorsolateral midbrain… (More)
Is this relevant?
1997
1997
Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.
Cholecystokinin (CCK) is one of the most abundant neuropeptides in the brain. It is found in the highest levels in cortical and… (More)
  • table I
  • table II
Is this relevant?
1997
1997
The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition
Pre-pulse inhibition (PPI) of the acoustic startle response is the diminution of the startle response when the startle stimulus… (More)
Is this relevant?
1996
1996
The CCK-B antagonist LY288513 blocks the effects of nicotine withdrawal on auditory startle.
In order to explore the potential clinical utility of CCK-B antagonists for the treatment of nicotine withdrawal symptoms, the… (More)
Is this relevant?
1996
1996
Central nervous system characterization of the new cholecystokinin<ce:inf loc=post>B</ce:inf> antagonist LY288513
 
Is this relevant?
1996
1996
Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo.
The potency and specificity of five proposed cholecystokinin-B receptor antagonists, YM022, RP73870, L-740,093, L-365,260 and… (More)
Is this relevant?
1993
1993
The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle.
In order to explore the potential clinical utility of CCK-B antagonists for the treatment of benzodiazepine withdrawal symptoms… (More)
Is this relevant?
1993
1993
Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain dopamine neurons.
The diphenylpyrazolidinone cholecystokinin (CCK)-B antagonist LY262691 has recently been demonstrated to decrease the number of… (More)
Is this relevant?